Risk factors for in-hospital mortality among patients hospitalized with COVID-19 and end-stage kidney disease.

IF 1.1 4区 医学 Q3 UROLOGY & NEPHROLOGY Clinical nephrology Pub Date : 2024-10-01 DOI:10.5414/CN111323
Jackson Heilbronn, Amir Abdipour, Giv Heidari-Bateni, Mohammad Sharif, Sahib Grewal, Sergio Infante, Kwame Agyeman, Zohreh Gholizadeh Ghozloujeh, Lida Gharibvand, Sayna Norouzi
{"title":"Risk factors for in-hospital mortality among patients hospitalized with COVID-19 and end-stage kidney disease.","authors":"Jackson Heilbronn, Amir Abdipour, Giv Heidari-Bateni, Mohammad Sharif, Sahib Grewal, Sergio Infante, Kwame Agyeman, Zohreh Gholizadeh Ghozloujeh, Lida Gharibvand, Sayna Norouzi","doi":"10.5414/CN111323","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The mortality rate for -COVID-19 infection varies significantly depending on age and comorbidities but remains high in hospitalized patients overall. Several retrospective studies have identified patients with end-stage kidney disease (ESKD) to be at increased risk. The objective of this study was to study in-hospital outcomes of ESKD patients at an academic medical center and identify characteristics that place them at a higher risk for in-hospital mortality.</p><p><strong>Materials and methods: </strong>A retrospective chart review was conducted including adult patients (≥ 18 years old) admitted to Loma Linda Medical Center for COVID-19 infection with a previous diagnosis of ESKD. Patients with prior kidney transplants were excluded. The main outcome of this study was the rate of in-hospital mortality.</p><p><strong>Results: </strong>21 of the 91 patients died with a mortality rate of 23%. Age, D-dimer > 0.4 µg/mL, ejection fraction less than 50%, and ferritin > 300 ng/mL were predictors for mortality in unadjusted univariate analysis. Adjusted multivariable analysis demonstrated that only an ejection fraction of less than 50% was associated with increased mortality risk.</p><p><strong>Conclusion: </strong>Cardiovascular disease is the leading cause of mortality for ESKD patients and also places them at increased risk of mortality in the setting of severe COVID-19 infection.</p>","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":" ","pages":"187-191"},"PeriodicalIF":1.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CN111323","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: The mortality rate for -COVID-19 infection varies significantly depending on age and comorbidities but remains high in hospitalized patients overall. Several retrospective studies have identified patients with end-stage kidney disease (ESKD) to be at increased risk. The objective of this study was to study in-hospital outcomes of ESKD patients at an academic medical center and identify characteristics that place them at a higher risk for in-hospital mortality.

Materials and methods: A retrospective chart review was conducted including adult patients (≥ 18 years old) admitted to Loma Linda Medical Center for COVID-19 infection with a previous diagnosis of ESKD. Patients with prior kidney transplants were excluded. The main outcome of this study was the rate of in-hospital mortality.

Results: 21 of the 91 patients died with a mortality rate of 23%. Age, D-dimer > 0.4 µg/mL, ejection fraction less than 50%, and ferritin > 300 ng/mL were predictors for mortality in unadjusted univariate analysis. Adjusted multivariable analysis demonstrated that only an ejection fraction of less than 50% was associated with increased mortality risk.

Conclusion: Cardiovascular disease is the leading cause of mortality for ESKD patients and also places them at increased risk of mortality in the setting of severe COVID-19 infection.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19 和终末期肾病住院患者院内死亡的风险因素。
目的:COVID-19 感染的死亡率因年龄和并发症的不同而有很大差异,但在住院患者中的总体死亡率仍然很高。一些回顾性研究发现,终末期肾病(ESKD)患者的风险更高。本研究的目的是研究一家学术医疗中心的终末期肾病(ESKD)患者的院内预后,并确定导致他们院内死亡风险较高的特征:研究人员对洛马琳达医疗中心因感染 COVID-19、既往诊断为 ESKD 而入院的成年患者(≥ 18 岁)进行了回顾性病历审查。既往接受过肾移植的患者除外。研究的主要结果是院内死亡率。结果:91 名患者中有 21 人死亡,死亡率为 23%。在未经调整的单变量分析中,年龄、D-二聚体> 0.4 µg/mL、射血分数低于50%和铁蛋白> 300 ng/mL是死亡率的预测因素。调整后的多变量分析表明,只有射血分数小于 50%与死亡风险增加有关:结论:心血管疾病是 ESKD 患者死亡的主要原因,同时也增加了他们在 COVID-19 严重感染情况下的死亡风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical nephrology
Clinical nephrology 医学-泌尿学与肾脏学
CiteScore
2.10
自引率
9.10%
发文量
138
审稿时长
4-8 weeks
期刊介绍: Clinical Nephrology appears monthly and publishes manuscripts containing original material with emphasis on the following topics: prophylaxis, pathophysiology, immunology, diagnosis, therapy, experimental approaches and dialysis and transplantation.
期刊最新文献
Spontaneous remission of de novo membranous nephropathy in post-allogeneic hematopoietic stem cell transplantation patients: A report of two cases. Impact of depression on clinical outcomes of peritoneal dialysis: A systematic review and meta-analysis. Renal involvement in genetic neurocutaneous syndromes. Drug-induced acute tubulointerstitial nephritis: Serial C-reactive protein measurements might predict the course of acute kidney injury. Microarray analysis of microRNA profiles for assessing the therapeutic effects of sodium thiosulfate on end-stage renal disease combined with coronary artery calcification.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1